UNSPSC 51291708: Setazindol

This classification denotes an anorexiant with the molecular formula C15H16ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92D9H0A3WN, chemically known as alpha-(4-chlorophenyl)-2-((methylamino)methyl)benzenemethanol, hydrochloride but generally known as setazindol, which bears US NIH Compound Identifier 193099. European Medicines Agency schedules Setazindol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10501MIG.

UNSPSC 51291708 Setazindol is a Commodity code that, based on recent state and local solicitations, does not reflect actual procurement activity for the pharmaceutical product named in the code. Instead, state and local buyers under this code designation are acquiring naloxone, safe drug deactivation systems, and broader generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing channels. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts for participating state and local agencies. Procurement is driven by public health initiatives, community health support, and government employee and retiree pharmacy benefit programs. Vendors must meet federal compliance requirements including cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, E-Verify confirmation, and FDA product standards; many contracts also require workers' compensation and commercial general liability insurance in the $2 million to $5 million range.

Recent activity appears concentrated in Florida and Minnesota, with Texas conducting preliminary market research. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, and a contract effective date of July 1, 2026. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Commodity code's recent posting history suggests modest activity; the mismatch between the code name (Setazindol, a specific pharmaceutical compound) and the scope of actual procurement (naloxone, drug deactivation systems, and broad generic pharmaceutical categories) indicates that state and local buyers are using this code to tag diverse pharmaceutical procurement outside its nominal scope.